Straipsniai su viešo pasiekiamumo įpareigojimais - David IlsonSužinokite daugiau
Niekur nepasiekiama: 6
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer
IS Sarkaria, NP Rizk, MS Bains, LH Tang, DH Ilson, BI Minsky, VW Rusch
Annals of surgery 249 (5), 764-767, 2009
Įpareigojimai: US National Institutes of Health
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
MA Shah, DG Power, HL Kindler, KD Holen, MM Kemeny, DH Ilson, ...
Investigational new drugs 29, 1475-1481, 2011
Įpareigojimai: US National Institutes of Health
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
GY Ku, DH Ilson, LH Schwartz, M Capanu, E O’Reilly, MA Shah, ...
Cancer chemotherapy and pharmacology 62, 875-880, 2008
Įpareigojimai: US National Institutes of Health
Advances in the treatment of gastric cancer
DH Ilson
Current opinion in gastroenterology 33 (6), 473-476, 2017
Įpareigojimai: UK Medical Research Council
Advances in the treatment of gastric cancer
DH Ilson
Current Opinion in Gastroenterology 36 (6), 525-529, 2020
Įpareigojimai: UK Medical Research Council
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
RH Moy, M Greally, JF Chou, J Li, AM Desai, SB Chalasani, E Won, ...
Cancer Chemotherapy and Pharmacology 89 (2), 255-265, 2022
Įpareigojimai: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Kur nors pasiekiama: 67
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised …
DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, ...
The lancet oncology 18 (11), 1467-1482, 2017
Įpareigojimai: US National Institutes of Health
Genetic predictors of response to systemic therapy in esophagogastric cancer
YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ...
Cancer discovery 8 (1), 49-58, 2018
Įpareigojimai: US Department of Defense, US National Institutes of Health
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ...
The Lancet Oncology 21 (6), 821-831, 2020
Įpareigojimai: US Department of Defense, US National Institutes of Health
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
Įpareigojimai: German Research Foundation
Zolbetuximab plus CAPOX in CLDN18. 2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
MA Shah, K Shitara, JA Ajani, YJ Bang, P Enzinger, D Ilson, F Lordick, ...
Nature medicine 29 (8), 2133-2141, 2023
Įpareigojimai: US National Institutes of Health
Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical …
M Suntharalingam, K Winter, D Ilson, AP Dicker, L Kachnic, A Konski, ...
JAMA oncology 3 (11), 1520-1528, 2017
Įpareigojimai: US National Institutes of Health
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
F Sanchez-Vega, JF Hechtman, P Castel, GY Ku, Y Tuvy, H Won, CJ Fong, ...
Cancer discovery 9 (2), 199-209, 2019
Įpareigojimai: US Department of Defense, US National Institutes of Health
Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of …
CS Fuchs, D Niedzwiecki, HJ Mamon, JE Tepper, X Ye, RS Swanson, ...
Journal of Clinical Oncology 35 (32), 3671-3677, 2017
Įpareigojimai: US National Institutes of Health
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma
RC Fields, VE Strong, M Gönen, KA Goodman, NP Rizk, DP Kelsen, ...
British journal of cancer 104 (12), 1840-1847, 2011
Įpareigojimai: US National Institutes of Health
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
DH Ilson, D Kelsen, M Shah, G Schwartz, DA Levine, J Boyd, M Capanu, ...
Cancer 117 (7), 1409-1414, 2011
Įpareigojimai: US National Institutes of Health
Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American …
P Sharma, DA Katzka, N Gupta, J Ajani, N Buttar, A Chak, D Corley, ...
Gastroenterology 149 (6), 1599-1606, 2015
Įpareigojimai: US National Institutes of Health, US Department of Veterans Affairs
CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers
PC Enzinger, BA Burtness, D Niedzwiecki, X Ye, K Douglas, DH Ilson, ...
Journal of Clinical Oncology 34 (23), 2736-2742, 2016
Įpareigojimai: US National Institutes of Health
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
HP Safran, K Winter, DH Ilson, D Wigle, T DiPetrillo, MG Haddock, ...
The Lancet Oncology 23 (2), 259-269, 2022
Įpareigojimai: US National Institutes of Health
Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
M Greally, JF Chou, WK Chatila, M Margolis, M Capanu, JF Hechtman, ...
Clinical cancer research 25 (20), 6160-6169, 2019
Įpareigojimai: US National Institutes of Health
Leidyklos ir finansavimo informaciją automatiškai nustato kompiuterio programa